Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pre-disease State of Obese Type 2 Diabetes Mellitus
NCT06495814Phase 2Not yet recruiting
- Start
- Jul 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of jinlida in impaired glucose tolerance (IGT) (6 arms). Primary endpoint: Incidence of diabetes at 12 months. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
jinlida
03
Conditions
impaired glucose tolerance (IGT)
Beyond the preview
Go deeper on NCT06495814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06495814.